{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:30:45Z","timestamp":1777307445846,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Idiopathic pulmonary fibrosis (IPF) is a chronically progressive fibrotic pulmonary disease characterized by an uncertain etiology, a poor prognosis, and a paucity of efficacious treatment options. Dexmedetomidine (Dex), an anesthetic-sparing alpha-2 adrenoceptor (\u03b12AR) agonist, plays a crucial role in organ injury and fibrosis. However, the underlying mechanisms of IPF remain unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In our study, the role of Dex in murine pulmonary fibrosis models was determined by Dex injection intraperitoneally in vivo. Fibroblast activation and myofibroblast differentiation were assessed after Dex treatment in vitro. The activation of MAPK pathway and the expression of Adenosine A2B receptor (ADORA2B) were examined in lung myofibroblasts. Moreover, the role of ADORA2B in Dex suppressing myofibroblast differentiation and pulmonary fibrosis was determined using the ADORA2B agonist BAY60-6583.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results revealed that Dex could inhibit Bleo-induced pulmonary fibrosis in mice. In vitro studies revealed that Dex suppressed TGF-\u03b2-mediated MAPK pathway activation and myofibroblast differentiation. Furthermore, Dex inhibits myofibroblast differentiation and pulmonary fibrosis via downregulating ADORA2B expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest Dex as a potential therapeutic agent for pulmonary fibrosis. Dex may alleviate lung fibrosis and myofibroblast differentiation through the ADORA2B-mediated MAPK signaling pathway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02513-3","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:02:37Z","timestamp":1693288957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaofan","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lvya","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"7","key":"2513_CR1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","volume":"174","author":"G RAGHU","year":"2006","unstructured":"Raghu G, Weycker D. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"2513_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-med-042711-142004","volume":"64","author":"DA STEELE M P, SCHWARTZ","year":"2013","unstructured":"Steele M P, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2013;64:265\u201376.","journal-title":"Annu Rev Med"},{"key":"2513_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","volume":"9","author":"PJ WOLTERS","year":"2014","unstructured":"Wolters PJ, Collard H R. Jones K D. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157\u201379.","journal-title":"Annu Rev Pathol"},{"issue":"22","key":"2513_CR4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L RICHELDI","year":"2014","unstructured":"Richeldi L, Du Bois R M, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"22","key":"2513_CR5","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"JR KING T E","year":"2014","unstructured":"King T E JR, Bradford W Z, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"6","key":"2513_CR6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00000542-199212000-00013","volume":"77","author":"JP BELLEVILLE","year":"1992","unstructured":"Belleville JP, Ward D S, Bloor B C, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992;77(6):1125\u201333.","journal-title":"Anesthesiology"},{"issue":"5","key":"2513_CR7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/00000542-200011000-00030","volume":"93","author":"T KAMIBAYASHI","year":"2000","unstructured":"Kamibayashi T, Maze M. Clinical uses of alpha2 -adrenergic agonists. Anesthesiology. 2000;93(5):1345\u20139.","journal-title":"Anesthesiology"},{"issue":"8","key":"2513_CR8","doi-asserted-by":"crossref","first-page":"14068","DOI":"10.1002\/jcp.28096","volume":"234","author":"J SHA","year":"2019","unstructured":"Sha J, Feng X, Chen Y, et al. Dexmedetomidine improves acute stress-induced liver injury in rats by regulating MKP-1, inhibiting NF-\u03baB pathway and cell apoptosis. J Cell Physiol. 2019;234(8):14068\u201378.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2513_CR9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.resuscitation.2007.01.032","volume":"74","author":"H OKADA","year":"2007","unstructured":"Okada H, Kurita T, Mochizuki T, et al. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation. 2007;74(3):538\u201345.","journal-title":"Resuscitation"},{"issue":"15","key":"2513_CR10","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1161\/CIRCULATIONAHA.112.000936","volume":"127","author":"F JI","year":"2013","unstructured":"Ji F, Li Z. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation. 2013;127(15):1576\u201384.","journal-title":"Circulation"},{"issue":"2","key":"2513_CR11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/08941939.2011.603817","volume":"25","author":"Z YOU","year":"2012","unstructured":"You Z, Feng D, Xu H, et al. Nuclear factor-kappa B mediates one-lung ventilation-induced acute lung injury in rabbits. J Invest Surg. 2012;25(2):78\u201385.","journal-title":"J Invest Surg"},{"key":"2513_CR12","doi-asserted-by":"crossref","unstructured":"Chen M, Yan X T Yel et al. Dexmedetomidine Ameliorates Lung Injury Induced by Intestinal Ischemia\/Reperfusion by Upregulating Cannabinoid Receptor 2, Followed by the Activation of the Phosphatidylinositol 3-Kinase\/Akt Pathway. Oxid Med Cell Longev, 2020, 2020: 6120194.","DOI":"10.1155\/2020\/6120194"},{"issue":"3","key":"2513_CR13","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1186\/cc10283","volume":"15","author":"J GU","year":"2011","unstructured":"Gu J, Sun P, Zhao H, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care. 2011;15(3):R153.","journal-title":"Crit Care"},{"key":"2513_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2018.05.003","volume":"207","author":"Q LI","year":"2018","unstructured":"Li Q, Chen C, Chen X, et al. Dexmedetomidine attenuates renal fibrosis via \u03b12-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia\/reperfusion. Life Sci. 2018;207:1\u20138.","journal-title":"Life Sci"},{"issue":"2","key":"2513_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/ALN.0000000000001135","volume":"125","author":"YEH Y C","year":"2016","unstructured":"Yeh Y C, Wu C Y, Cheng Y J, et al. Effects of Dexmedetomidine on Intestinal Microcirculation and Intestinal Epithelial Barrier in Endotoxemic Rats. Anesthesiology. 2016;125(2):355\u201367.","journal-title":"Anesthesiology"},{"issue":"2","key":"2513_CR16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","volume":"74","author":"CE AP I J, JACOBSON K A, M\u00fcLLER","year":"2022","unstructured":"Ap I J, Jacobson K A, M\u00fcller CE, et al. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: a further Update. Pharmacol Rev. 2022;74(2):340\u201372.","journal-title":"Pharmacol Rev"},{"key":"2513_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2019.01.003","volume":"198","author":"VECCHIO E A","year":"2019","unstructured":"Vecchio E A, White P J. May L T. The adenosine A(2B) G protein-coupled receptor: recent advances and therapeutic implications. Pharmacol Ther. 2019;198:20\u201333.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2513_CR18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2174\/092986708783955392","volume":"15","author":"G VASS","year":"2008","unstructured":"Vass G, Horv\u00e1th I. Adenosine and adenosine receptors in the pathomechanism and treatment of respiratory diseases. Curr Med Chem. 2008;15(9):917\u201322.","journal-title":"Curr Med Chem"},{"issue":"8","key":"2513_CR19","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1172\/JCI27303","volume":"116","author":"H SUN C X, ZHONG","year":"2006","unstructured":"Sun C X, Zhong H, Mohsenin A, et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest. 2006;116(8):2173\u201382.","journal-title":"J Clin Invest"},{"issue":"1","key":"2513_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12951-019-0478-y","volume":"17","author":"B LIU","year":"2019","unstructured":"Liu B, Bing Q, LI S, et al. Role of A(2B) adenosine receptor-dependent adenosine signaling in multi-walled carbon nanotube-triggered lung fibrosis in mice. J Nanobiotechnol. 2019;17(1):45.","journal-title":"J Nanobiotechnol"},{"key":"2513_CR21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fphar.2018.00054","volume":"9","author":"C GIACOMELLI","year":"2018","unstructured":"Giacomelli C, Daniele S, Romei C, et al. The A(2B) adenosine receptor modulates the epithelial- mesenchymal transition through the balance of cAMP\/PKA and MAPK\/ERK pathway activation in human epithelial lung Cells. Front Pharmacol. 2018;9:54.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2513_CR22","first-page":"1257","volume":"138","author":"C KUHN","year":"1991","unstructured":"Kuhn C, Mcdonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991;138(5):1257\u201365.","journal-title":"Am J Pathol"},{"issue":"5","key":"2513_CR23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S1470-2045(05)70168-6","volume":"6","author":"FANG J Y","year":"2005","unstructured":"Fang J Y, Richardson B C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322\u20137.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2513_CR24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","volume":"13","author":"JS ARTHUR","year":"2013","unstructured":"Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679\u201392.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2513_CR25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1164\/ajrccm.163.1.2005069","volume":"163","author":"S HASHIMOTO","year":"2001","unstructured":"Hashimoto S, Gon Y, Takeshita I, et al. Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med. 2001;163(1):152\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"2513_CR26","doi-asserted-by":"crossref","first-page":"115500","DOI":"10.1016\/j.taap.2021.115500","volume":"418","author":"H GUO","year":"2021","unstructured":"Guo H, Jian Z, Liu H, et al. TGF-\u03b21-induced EMT activation via both smad-dependent and MAPK signaling pathways in Cu-induced pulmonary fibrosis. Toxicol Appl Pharmacol. 2021;418:115500.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"2513_CR27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrendo.2015.10","volume":"11","author":"L ANTONIOLI","year":"2015","unstructured":"Antonioli L, Blandizzi C, Cs\u00f3ka B, et al. Adenosine signalling in diabetes mellitus\u2013pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2015;11(4):228\u201341.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2513_CR28","first-page":"343","volume":"96","author":"M BREDE","year":"2004","unstructured":"Brede M, Philipp M, Knaus A, et al. alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. Biol Cell. 2004;96(5):343\u20138.","journal-title":"Biol Cell"},{"issue":"7","key":"2513_CR29","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.bjp.0701520","volume":"122","author":"JC HUNTER","year":"1997","unstructured":"Hunter JC, Fontana D J, Hedley L R, et al. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol. 1997;122(7):1339\u201344.","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"2513_CR30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.08.044","volume":"502","author":"D MA","year":"2004","unstructured":"Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004;502(1\u20132):87\u201397.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2513_CR31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1213\/01.ane.0000194301.79118.e9","volume":"102","author":"A PARIS","year":"2006","unstructured":"Paris A, Mantz J, Tonner P H, et al. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg. 2006;102(2):456\u201361.","journal-title":"Anesth Analg"},{"issue":"3","key":"2513_CR32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"COLLARD H R","year":"2016","unstructured":"Collard H R, Ryerson C J, Corte T J, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2513_CR33","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jmv.26634","volume":"93","author":"C ZHANG","year":"2021","unstructured":"Zhang C, Wu Z, Li JW, et al. Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol. 2021;93(3):1378\u201386.","journal-title":"J Med Virol"},{"issue":"8","key":"2513_CR34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","volume":"8","author":"RG GEORGE P M, WELLS A U, JENKINS","year":"2020","unstructured":"George P M, Wells A U, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807\u201315.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"2513_CR35","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1097\/CCM.0000000000001035","volume":"43","author":"J CUI","year":"2015","unstructured":"Cui J, Zhao H. Dexmedetomidine attenuates Bilirubin-Induced Lung alveolar epithelial cell death in Vitro and in Vivo. Crit Care Med. 2015;43(9):e356\u2013368.","journal-title":"Crit Care Med"},{"issue":"1","key":"2513_CR36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12967-018-1455-1","volume":"16","author":"J LI","year":"2018","unstructured":"Li J, Chen Q, He X, et al. Dexmedetomidine attenuates lung apoptosis induced by renal ischemia-reperfusion injury through \u03b1(2)AR\/PI3K\/Akt pathway. J Transl Med. 2018;16(1):78.","journal-title":"J Transl Med"},{"key":"2513_CR37","doi-asserted-by":"crossref","first-page":"101954","DOI":"10.1016\/j.redox.2021.101954","volume":"41","author":"J SHI","year":"2021","unstructured":"Shi J, Yu T, Song K, et al. Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a\/HO-1 signaling pathway. Redox Biol. 2021;41:101954.","journal-title":"Redox Biol"},{"issue":"13","key":"2513_CR38","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1111\/jcmm.16614","volume":"25","author":"L XU","year":"2021","unstructured":"Xu L, Li T, Chen Q, et al. The \u03b12AR\/Caveolin-1\/p38MAPK\/NF-\u03baB axis explains dexmedetomidine protection against lung injury following intestinal ischaemia-reperfusion. J Cell Mol Med. 2021;25(13):6361\u201372.","journal-title":"J Cell Mol Med"},{"key":"2513_CR39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biopha.2018.05.104","volume":"105","author":"J WANG","year":"2018","unstructured":"Wang J, He F, Chen L, et al. Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK\/AP-1 pathways. Biomed Pharmacother. 2018;105:37\u201344.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2513_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","volume":"63","author":"FREDHOLM B B","year":"2011","unstructured":"Fredholm B B, AP I J, Jacobson K A, et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors\u2013an update. Pharmacol Rev. 2011;63(1):1\u201334.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2513_CR41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1165\/rcmb.2003-0118OC","volume":"30","author":"H ZHONG","year":"2004","unstructured":"Zhong H, Belardinelli L, Maa T, et al. A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol. 2004;30(1):118\u201325.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"2513_CR42","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1172\/JCI122106","volume":"129","author":"T WENG","year":"2019","unstructured":"Weng T, Ko J, Masamha C P, et al. Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation. J Clin Invest. 2019;129(5):1984\u201399.","journal-title":"J Clin Invest"},{"issue":"4","key":"2513_CR43","first-page":"772","volume":"119","author":"M K\u00f6NIGSHOFF","year":"2009","unstructured":"K\u00f6Nigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119(4):772\u201387.","journal-title":"J Clin Invest"},{"issue":"2","key":"2513_CR44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1165\/rcmb.2021-0257OC","volume":"66","author":"S HUANG","year":"2022","unstructured":"Huang S, Lai X. Asporin promotes TGF-\u03b2-induced lung myofibroblast differentiation by facilitating Rab11-Dependent recycling of T\u03b2RI. Am J Respir Cell Mol Biol. 2022;66(2):158\u201370.","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02513-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T22:14:45Z","timestamp":1700345685000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02513-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2513"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02513-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures conducted in this work comply with the ethical standards of the institution and\/or the National Research Council.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}